Svizzera - francese - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - lenalidomidum - gélules - lenalidomidum 20 mg, lactosum 244.5 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.8 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 132, e 172 (flavum), drucktinte: lacca, propylenglycolum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

Svizzera - francese - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - lenalidomidum - gélules - lenalidomidum 25 mg, lactosum 200 mg, cellulosum microcristallinum, carmellosum natricum seulement liés corresp. sodium 0,8 mg, magnésium stearas, kapselhülle: gélatine, e-171, drucktinte: lacca, propylenglycolum, e 172 (noir), kalii hydroxidum, pour une petite boîte. - onkologikum - synthetika

Svizzera - francese - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - lenalidomidum - gélules - lenalidomidum 2.5 mg, lactosum 20.0 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.204 mg, magnesii stearas, kapselhülle: gelatina, e 132, titanii dioxidum, e 172 (flavum), drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

Svizzera - francese - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - lenalidomidum - gélules - lenalidomidum 5.0 mg, lactosum 40.0 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.408 mg, magnesii stearas, kapselhülle: gelatina, titanii dioxidum, drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

Svizzera - francese - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - lenalidomidum - gélules - lenalidomidum 7.5 mg, lactosum 60.0 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.612 mg, magnesii stearas, kapselhülle: gelatina, titanii dioxidum, e 172 (flavum), drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

Svizzera - francese - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - lenalidomidum - gélules - lenalidomidum 10.0 mg, lactosum 80.0 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.816 mg, magnesii stearas, kapselhülle: gelatina, e 132, titanii dioxidum, e 172 (flavum), drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

Svizzera - francese - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - lenalidomidum - gélules - lenalidomidum 15.0 mg, lactosum 120.0 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 1.224 mg, magnesii stearas, kapselhülle: gelatina, e 132, titanii dioxidum, drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

Svizzera - francese - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - lenalidomidum - gélules - lenalidomidum 20.0 mg, lactosum 160.0 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 1.632 mg, magnesii stearas, kapselhülle: gelatina, e 132, titanii dioxidum, e 172 (flavum), drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

Svizzera - francese - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - lenalidomidum - gélules - lenalidomidum 25.0 mg, lactosum 200.0 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 2.04 mg, magnesii stearas, kapselhülle: gelatina, titanii dioxidum, drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

Unione Europea - francese - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - immunosuppresseurs - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) est indiqué pour le traitement de patients adultes atteints de traitement préalable de myélome multiple qui ne sont pas éligibles pour une transplantation. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) est indiqué pour le traitement de patients adultes atteints de traitement préalable de myélome multiple qui ne sont pas éligibles pour une transplantation. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).